Ensign Peak Advisors, Inc Travere Therapeutics, Inc. Transaction History

Ensign Peak Advisors, Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$17.82 - $22.89 $585,529 - $752,119	32,858 Added 42.55%	110,088 $2.48 Million
Q4 2022 Feb 13, 2023	SELL	$18.47 - $26.14 $371,247 - $525,414	-20,100 Reduced 20.65%	77,230 $1.62 Million
Q3 2022 Nov 14, 2022	BUY	$22.91 - $28.63 $468,074 - $584,939	20,431 Added 26.57%	97,330 $2.4 Million
Q2 2022 Aug 12, 2022	BUY	$20.94 - $30.01 $1.38 Million - $1.98 Million	65,819 Added 594.03%	76,899 $1.86 Million
Q1 2022 May 16, 2022	BUY	$23.61 - $30.6 $261,598 - $339,048	11,080 New	11,080 $286,000

199

85.2M

776K

912K

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.35B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ensign Peak Advisors, Inc with notifications on news.